Investor Relations

NRx Pharmaceuticals is a clinical-stage, biopharmaceutical company developing therapeutics for the treatment of central nervous system disorders, specifically suicidal depression and post-traumatic stress disorder (PTSD). The company’s lead program NRX-101, is an oral, fixed dosed combination of D-cycloserine and lurasidone, which targets the brain’s NMDA receptor.

The company has filed an Abbreviated New Drug Application (ANDA) for NRX-100, preservative-free IV ketamine and has initiated filing of an NDA for NRX-100 in people with suicidal depression.

NRx Pharmaceuticals (Nasdaq: NRXP), formerly NeuroRx, is traded on the Nasdaq Global Select Exchange.

Stock Data

Volume
Market Cap
Currency in USD.

Corporate Presentation

Click here to view our corporate presentation or on the image below
Corporate Presentation

Detailed Quote

Minimum 15 minutes delayed. Source: LSEG

Recent News

NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression
September 30, 2026
DARPA states that the program, if successful, will fundamentally change the Standard of Care for Treatment Resistant Depression. The Military has recognized that current treatments for depression are not deployable in operational military settings. The SPARC-TMS Single Day treatment protocol, which

For more news and articles, visit our news page.

IP Portfolio
View Our Pipeline
Contact NRx Pharmaceuticals